Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of JS207 + JS007 as first-line treatment for advanced hepatocellular carcinoma
CTR20251351Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JS207, JS007 in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jun 2025; status: active.
02
Drugs
JS207JS007
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20251351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251351.